The CASP6 Knockout 143B Polyclonal Cells consist of a heterogeneous population of 143B human osteosarcoma cells in which the CASP6 gene has been disrupted using CRISPR/Cas9-mediated gene editing, generating a pooled knockout model that eliminates caspase-6 function. This polyclonal configuration minimizes clonal bias and provides a robust system for studying loss-of-function effects on executioner caspase-mediated apoptosis, inflammation, and related signaling networks. The knockout pool is suitable for a variety of functional and biochemical assays.
The 143B cell line is a well-established human osteosarcoma model derived from the HOS parental line, exhibiting thymidine kinase deficiency (TK-negative) and characteristic features of malignant bone tumors. These cells display aggressive proliferation, high metastatic potential, and tumorigenicity in vivo, making them a relevant platform for investigating osteosarcoma biology, therapeutic responses, and mechanisms of drug resistance. The TK-negative phenotype also facilitates negative selection strategies in stable gene expression studies.
CASP6 encodes the executioner caspase-6, which orchestrates apoptosis through cleavage of lamin A/C and PARP1, resulting in nuclear dismantling and DNA fragmentation. It is proteolytically activated by upstream initiator caspases-8 and -9, and by granzyme B, and its expression is transcriptionally regulated by p53. Caspase-6 activity is tempered by inhibitors including XIAP and Bcl-2 family members, and it intersects with inflammasome and NF-kB pathways. Notably, caspase-6 also cleaves huntingtin, generating neurotoxic fragments implicated in Huntington??s disease.
In the 143B osteosarcoma context, ablation of CASP6 provides a specialized tool to investigate how loss of executioner caspase function influences malignant phenotypes. Osteosarcoma cells often subvert apoptotic programs to survive chemotherapy and promote metastasis. This polyclonal knockout model enables detailed analysis of caspase-6-dependent drug sensitivity, migration, and invasion, as well as the processing of substrates such as cytokeratin 18 and huntingtin. By studying these processes in a bone tumor environment, researchers can gain insights into the intersection of apoptosis defects and tumor aggressiveness.
Key applications include apoptosis pathway analysis, chemoresistance screening, neurodegeneration modeling, and inflammasome research. Compatible assays encompass western blotting for cleaved lamin A/C and PARP1, caspase activity measurements, apoptosis detection, RT-qPCR, and functional drug sensitivity, migration, and invasion assays. The polyclonal knockout pool enables study of heterogeneous responses, reflecting physiological complexity. For further technical details or customized inquiries, please contact Ascent Research.
